Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis pain
使用 CardioLRX 導致心包炎疼痛的主要療效終點顯著降低
CardiolRx also shown to reduce inflammation in patients with elevated CRP
CardiolRX 還被證明可以減輕 CRP 升高患者的炎症
89% of patients have continued into the extension phase of the study
89% 的患者已進入研究的延期階段
Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ("TP"), as well as normalization of inflammation - as measured by C-reactive protein ("CRP") - in 80% of patients with elevated CRP at baseline.
安大略省多倫多--（Newsfile Corp.，2024年6月13日）——專注於治療心臟病的抗炎和抗纖維化療法研究和臨床開發的臨床階段生命科學公司Cardiol Therapeutics Inc.（納斯達克股票代碼：CRDL）（多倫多證券交易所股票代碼：CRDL）（“Cardiol” 或 “公司”）今天報告了其二期開放標籤Maveric-Pilot研究的8周臨床數據對有症狀的複發性心包炎患者施用CardioLRx的影響。數據顯示，在8周治療期（“TP”）結束時，患者報告的心包炎疼痛的主要療效終點顯著降低，根據C反應蛋白（“CRP”）的測量，在基線時80％的CRP升高患者中，炎症恢復正常。